<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        309-212-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CO-IRBETEL 312.5 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        65.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI WINTHROP INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI WINTHROP INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CoIrbetel is a combination of two active substances, irbesartan and hydrochlorothiazide. Irbesartan belongs to a group of medicines known as angiotensin II receptor antagonists. Angiotensin II is a substance produced in the body that binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin II to these receptors, causing the blood vessels to relax and the blood pressure to lower. Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure. The two active ingredients in CoIrbetel work together to lower blood pressure further than if either was given alone. Therapeutic indications CoIrbetel is used in adult patients CoIrbetel is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take CoIrbetel:</strong></p><p>&bull; if you are allergic (hypersensitive) to irbesartan or any of the other ingredients of CoIrbetel &bull; if you are allergic (hypersensitive) to hydrochlorothiazide or any other sulfonamide-derived medicines;</p><p>&bull; if you are more than 3 months pregnant. (It is also better to avoid CoIrbetel in early pregnancy &ndash; see pregnancy section); &bull; if you have severe liver or kidney problems; &bull; if you have difficulty in producing urine; &bull; if your doctor determines that you have persistently high calcium or low potassium levels in your blood.</p><p>CoIrbetel should not be given to children and adolescents (under 18 years).</p><p><strong>Appropriate precautions for use; special warnings Take special care with CoIrbetel</strong></p><p>&bull; if you get excessive vomiting or diarrhoea; &bull; if you suffer from kidney problems or have a kidney transplant; &bull; if you suffer from heart problems; &bull; if you suffer from liver problems; &bull; if you suffer from diabetes; &bull; if you suffer from lupus erythematosus (also known as lupus or SLE); &bull; if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, &bull; in turn, an increase in blood pressure). &bull; The active ingredient hydrochlorothiazide can cause an unusual reaction, resulting in a decrease in vision and eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking CoIrbetel. This can lead to permanent vision impairment, if not treated &bull; If you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long-term use with high doses, may increase the risk of some types of skin and lip cancer (nonmelanoma skin cancer). Protect your skin from sun exposure and UV rays while taking CoIrbetel.</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Combination therapy of ACEI (Angiotensin Converting Enzyme inhibitors) and ARB (Angiotensin II Receptor Blocker) drugs may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems. You must tell your doctor if you think you are (or might become) pregnant. CoIrbetel is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p><strong>You should also tell your doctor:</strong></p><p>&bull; if you are on a low-salt diet; &bull; if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in CoIrbetel); &bull; if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal; &bull; if you are going to have an operation (surgery) or be given anaesthetics.&nbsp;</p><p>&bull; If you have changes in your vision or pain in one or both of your eyes while taking CoIrbetel. This could be a sign that you are developing glaucoma, increased pressure in your eye(s). You should discontinue CoIrbetel treatment and seek medical attention. The hydrochlorothiazide contained in this medicine could produce a positive result in an antidoping test.</p><p><strong>Using other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Diuretic agents such as the hydrochlorothiazide contained in CoIrbetel may have an effect on other medicines. Preparations containing lithium should not be taken with CoIrbetel without close supervision by your doctor.</p><p><strong>You may need to have blood checks if you take:</strong></p><p>&bull; potassium supplements,</p><p>&bull; salt substitutes containing potassium,</p><p>&bull; potassium sparing medicines or other diuretics (water tablets),</p><p>&bull; some laxatives,</p><p>&bull; medicines for the treatment of gout,</p><p>&bull; therapeutic vitamin D supplements,</p><p>&bull; medicines to control heart rhythm,</p><p>&bull; medicines for diabetes (oral agents or insulins)</p><p>, &bull; carbamazepine (a medicine for the treatment of epilepsy). It is also important to tell your doctor if you are taking other medicines to reduce your blood pressure, steroids, medicines to treat cancer, pain killers, arthritis medicines, or colestyramine and colestipol resins for lowering blood cholesterol.</p><p><strong>Taking CoIrbetel with food and drink CoIrbetel can be taken with or without food.</strong></p><p>Due to the hydrochlorothiazide contained in CoIrbetel, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Pregnancy:</strong></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking CoIrbetel before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of CoIrbetel. CoIrbetel is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. CoIrbetel is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely</p><p><strong>Driving and using machines</strong></p><p>No studies on the effects on the ability to drive and use machines have been performed. CoIrbetel is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before attempting to drive or use machines.</p><p><strong>Important information about some of the ingredients of CoIrbetel</strong></p><p>CoIrbetel contains lactose. If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take CoIrbetel exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Dosage The usual dose of CoIrbetel is one tablet a day. CoIrbetel will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough. Your doctor will instruct you how to switch from the previous treatment to CoIrbetel. Method of administration CoIrbetel is for oral use. Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water). You can take CoIrbetel with or without food. Try to take your daily dose at about the same time each day. It is important that you continue to take CoIrbetel until your doctor tells you otherwise. The maximal blood pressure lowering effect should be reached 6-8 weeks after beginning treatment. If you take more CoIrbetel than you should If you accidentally take too many tablets, contact your doctor immediately. Children should not take CoIrbetel CoIrbetel should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately. If you forget to take CoIrbetel If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, CoIrbetel can cause side effects, although not everybody gets them. Some of these effects may be serious and may require medical attention. Rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.</p><p><strong>if you get any of the above symptoms or get short of breath, stop taking CoIrbetel and contact your doctor immediately.</strong></p><p>Side effects reported in clinical studies for patients treated with CoIrbetel were: Common side effects (affect 1 to 10 users in 100) &bull; nausea/vomiting, &bull; abnormal urination, &bull; fatigue, &bull; dizziness (including when getting up from a lying or sitting position), &bull; blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).</p><p>&nbsp;</p><p><strong>If any of these side effects causes you problems, talk to your doctor.</strong></p><p>Uncommon side effects (affect 1 to 10 users in 1,000) &bull; diarrhoea, &bull; low blood pressure, &bull; fainting, &bull; heart rate increased, &bull; flushing, &bull; swelling, &bull; sexual dysfunction (problems with sexual performance), &bull; blood tests may show lowered levels of potassium and sodium in your blood. If any of these side effects causes you problems, talk to your doctor. Side effects reported since the launch of CoIrbetel Some undesirable effects have been reported since marketing of CoIrbetel. Undesirable effects where the frequency is not known are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat. Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported. As for any combination of two active substances, side effects associated with each individual component cannot be excluded.</p><p><strong>Side effects associated with irbesartan alone</strong></p><p>In addition to the side effects listed above, chest pain has also been reported.</p><p><strong>Side effects associated with hydrochlorothiazide alone</strong></p><p>Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of&nbsp;blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.&nbsp;</p><p>It is known that side effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>&bull; Sudden short sightedness. &bull; Sudden eye pain (acute angle-closure glaucoma). &bull; Choroidal effusion, acute myopia and secondary angle-closure glaucoma. &bull; skin and lip cancer (non-melanoma skin cancer)</p><p><strong>If any of the side effects gets serious,</strong> or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children. Do not use CoIrbetel after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month. Do not store above 30&deg;C. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CoIrbetel 150/12.5mg FC tablet: &bull; The active substances are irbesartan and hydrochlorothiazide. Each filmcoated tablet of CoIrbetel 150 mg/12.5 mg contains 150 mg irbesartan and 12.5mg hydrochlorothiazide. &bull; The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, red and yellow ferric oxides, carnauba wax. . CoIrbetel 300/12.5mg FC tablet : &bull; The active substances are irbesartan and hydrochlorothiazide. Each filmcoated tablet of CoIrbetel 300 mg/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide. &bull; The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, red and yellow ferric oxides, carnauba wax. CoIrbetel 300/12.5mg FC tablet : &bull; The active substances are irbesartan and hydrochlorothiazide. Each filmcoated tablet of CoIrbetel 300 mg/25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide.&nbsp;&bull; The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3350, red and yellow ferric oxides, carnauba wax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CoIrbetel 150/12.5mg FC tablet:
CoIrbetel 150 mg/12.5 mg film-coated tablets are peach, biconvex, ovalshaped, with a heart
debossed on one side and the number 2875 engraved on the other side..
CoIrbetel 300/12.5mg FC tablet:
CoIrbetel 300 mg/12.5 mg film-coated tablets are peach, biconvex, ovalshaped, with a heart
debossed on one side and the number 2876 engraved on the other side.
CoIrbetel 300/25mg FC tablet:
CoIrbetel 300 mg/25 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart
debossed on one side and the number 2788 engraved on the other side.
Pack sizes
CoIrbetel 150/12.5mg FC tablet:
CoIrbetel 150 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56,
84, 90 or 98 film-coated tablets. Unit dose blister packs of 56 x 1 film-coated tablet for
delivery in hospitals are also available.
Not all pack sizes may be marketed.
CoIrbetel 300/12.5mg FC tablet:
CoIrbetel 300 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56,
84, 90 or 98 film-coated tablets. Unit dose blister packs of 56 x 1 film-coated tablet for
delivery in hospitals are also available.
Not all pack sizes may be marketed
CoIrbetel 300/25mg FC tablet:
CoIrbetel 300 mg/25 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84,
90 or 98 film-coated tablets. Unit dose blister packs of 56 x 1 film-coated tablet for delivery
in hospitals are also available.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by: SANOFI. For: SPIMACO AlQassim pharmaceutical plant Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>الفئة الدوائية العالجية. كوإربيتل هو مزيج من مادتين فاعليتين هما اإلربزارتان والهيدروكلوروثيازيد.</p><p>ينتمي اإلبرزارتان إلى مجموعة من األدوية تعرف بمضادات مستقبالت االنجيوتنسين II الذي هو مادة تنتج في الجسم وترتبط بالمستقبالت في األوعية الدموية فتقلصها، مما يؤدي إلى ارتفاع في ضغط الدم. يمنع اإلربزارتان ارتباط االنجيوتنسين II بهذه المستقبالت مما يؤدي إلى ارتخاء األوعية الدموية وانخفاض ضغط الدم. وينتمي الهيدروكلوروثيازيد إلى مجموعة من األدوية (تدعى مدرات بول الثيازيد) تزيد النتائج البولي مما يخفض ضغط الدم. لتخفيض ضغط الدم أكثر مما لو وهكذا يعمل المركبان الفاعالن في كوإربيتل معا أعطي كل مركب لوحده. ً دواعي االستعمال العالجية: يستعمل كوإربيتل لعالج ضغط الدم المرتفع، عندما لم يؤمن العالج باإلربزارتان أو بالهيدروكلوروثيازيد لوحده التحكم المناسب لضغط الدم لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع االستعمال: ال تأخذ كوإربيتل &bull; إذا كنت مصابا بحساسية ضد اإلربزارتان أو ضد أي مكون آخر من مكونات كوإربيتل. بحساسية ضد الهيدروكلوروثيازيد أو ضد أي أدوية أخرى مشتقة من السلفوناميد. &bull; إذا كنت مصاباً &bull; إذا كنت حامالً ألكثر من 3 أشهر )يفضل كذلك تفادي كوإربيتل في األشهر األولى من الحمل&ndash; راجعي فقرة الحمل(. &bull; إذا كنت تعاني من اضطرابات حادة في الكبد أو الكلى. &bull; إذا كنت تعاني من صعوبة في التبول. &bull; إذا رأى طبيبك أن لديك معدالت عاليه من الكالسيوم أو معدالت منخفضة من البوتاسيوم في الدم بشكل دائم. ال ينبغي إعطاء كوإربيتل لألطفال والمراهقين )ما دون 18 عاماً) محاذير خاصة لالستعمال، تحذيرات خاصة: اعتمد عناية خاصة مع كوإربيتل. أعلم طبيبك في حال كنت تعاني من: - تقيؤ أو إسهال قوي. - مشاكل في الكلى أو إذا قمت بزراعة كلية. - مشاكل في القلب. - مشاكل في الكبد. - داء السكري. - الذأب الحمامي )المعروف أيضاً بالذأب)</p><p>- فرط األلدوستيرون )حالة ناتجة عن إنتاج مرتفع لهرمون األلدوستيرون مما يسبب احتباس الصوديوم الذي يسبب بدروه ارتفاعا (. ً في ضغط الدم يمكن أن يسبب هيدروكلوروثيازيد المكون النشط رد فعل غير عادي ، قد يؤدي إلى انخفاض في الرؤية وألم العين. قد تكون هذه أعراض زيادة الضغط في عينك ويمكن أن تحدث في غضون ساعات إلى أسابيع من تناول كوإربيتل. هذا يمكن أن يؤدي إلى ضعف البصر الدائم ، إذا لم يتم عالجه إذا كنت مصابًا بسرطان الجلد أو إذا كنت تعاني من أعراض جلدية غير متوقعة أثناء العالج. قد يزيد العالج باستخدام هيدروكلوروثيازيد ، وخاصة االستخدام طويل المدى بجرعات عالية ، من خطر اإلصابة ببعض أنواع سرطان الجلد والشفاه )سرطان الجلد غير الميالنيني(. احمي بشرتك من التعرض ألشعة الشمس واألشعة فوق البنفسجية أثناء تناول كوإربيتل. االنسداد المزدوج لنظام رينين-أنجيوتنسين-ألدوستيرون )RAAS:) االستخدام بشكل متزامن لمثبطات اإلنزيم المحول ألنجيوتنسين مع مضادات مستقبل أنجيوتنسين-II قد يسبب زيادة فى خطورة ارتفاع مستوى البوتاسيوم بالدم وتدهور فى وظائف الكلى وانخفاض ضغط الدم. لذلك, يجب عدم الجمع بين هذه األدوية عند ستخدام خصوصا لى. ً اال فى حالة المرضى المصابين بمشاكل بالك أو قد تصبحين حامالً( ال يوصى باستعمال كوإربيتل في األشهر األولى يجدر بك أن تعلمي طبيبك أيضا إذا كنت تعتقدن أنك ) من الحمل وال ينبغي أخذه إذا كنت حامالً ألكثر من 3 أشهر ألنه قد يسبب أذى خطير لطفلك إذا استعمل في هذه المرحلة )راجعي فقرة الحمل) ضا م طبيبك: ً يجدر بك أي أن تعل &bull; إذا كنت تتبع حمية منخفضة الملح. &bull; إذا كنت تعاني من أعراض مثل الظمأ غير الطبيعي وجفاف الفم والتعب العام والنعاس وألم العضالت أو المعص والغثيان والتقيؤ ودقة القلب السريعة غير الطبيعية قد تدل على مفعول مفرط للهيدروكلوروثيازيد )الذي يحتوي عليه كوإربيتل( &bull; إذا تعرضت لحساسية متزايدة حيال الشمس مع عوارض حرق الشمس )مثل االحمرار والحكاك والتورم والتنفط( تحصل بسرعة أكثر من العادة. &bull; إذا كنت ستخضع لعملية جراحية )جراحة( أو كنت ستعطى أدوية مخدرة. &bull; إن الهيدروكلوروثيازيد الذي يحتوي عليه هذا الدواء يمكن أن يعطي نتيجة إيجابية في فحص كشف تناول المنشطات. استعمال أدوية أخرى &bull; يجدر بك إعالم طبيبك بأي أدوية تتناولها أو تناولتها مؤخراً، بما فيها األدوية التي حصلت عليها من دون وصفة طبية. إن العوامل المدرة للبول مثل الهيدروكلوروثيازيد الذي يحتويه كوإربيتل يمكن أن تتفاعل مع أدوية أخرى. يجب عدم تناول المستحضرات التي تحتوي على الليثيوم مع كوإربيتل بدون مراقبة طبية دقيقة. قد تحتاج إلى أجراء فحص دم إذا كنت تتناول: &bull; مكمالت بوتاسيوم. &bull; بدائل الملح تحتوي على البوتاسيوم.</p><p>األدوية التي تحافظ على البوتاسيوم أو مدرات بول أخرى )أقراص الماء(. &bull; بعض الملينات. &bull; أدوية لعالج النقرس. &bull; مكمالت فيتامين د العالجية. &bull; أدوية ضبط النظم القلبي. &bull; أدوية السكري )األدوية الفموية أو األنسولين(. &bull; كاربامازيبين )دواء لمعالجة الصرع( &bull; من المهم أن يعرف طبيبك كذلك إذا كنت تتناول أدوية أخرى لتخفيض ضغط دمك أو ستيرويدات أو أدوية لعالج السرطان أو مهدئات ألم أو أدوية التهاب المفاصل أو راتنجات الكولستيبول لتخفيض كولستيرول الدم. أخذ كوإربيتل مع الطعام والشراب: يمكن أخذ كوإربيتل مع الطعام أو بدونه. بسبب الهيدروكلوروثيازيد الذي يحتوي عليه كوإربيتل ، إذا شربت االيثانول في خالل مرحلة العالج بهذا الدواء قد يزداد إحساسك بالدوار عند الوقوف بخاصة عندما تقف بعد الجلوس. الحمل واإلرضاع الحمل بيبك إذا كنت حامال أو إذا كنت تعتقدين أنك قد تصبحين حامالً طبيبك عادة بإيقاف يجب عليك إعالم ط . سوف ينصحك أو حالما تعرفين أنك حامل وسوف يطلب منك أخذ دواء آخر كوإربيتل . ال ينصح بأخذ كوإربيتل قبل أن تصبحي حامالً لطفلك إذا كوإربيتل في األشهر األولى من الحمل، كما ال ينبغي أخذه بعد الشهر الثالث من الحمل ألنه قد يسبب أذى خطيراً استعمل بعد الشهر الثالث من الحمل. اإلرضاع أعلمي طبيبك إذا كنت ترضعين أو على وشك البدء باإلرضاع ال ينصح بإعطاء كوإربيتل إلى األمهات المرضعات ال سيما إذا كان طفلك حديث الوالدة أو ولد قبل أوانه. القيادة واستعمال اآلالت لم يتم إجراء دراسات حول تأثيرات الدواء على القدرة على القيادة أو استعمال اآلالت. ولكن قد يصاب المريض بالدوار أو باإلرهاق خالل عالج ضغط الدم المرتفع. إذا واجهت هذا األمر، تحدث إلى طبيبك قبل محاولة القيادة أو استعمال اآلالت. معلومات مهمة حول بعض مكونات كوإربيتل يحتوي كوإربيتل على الالكتوز. إذا قال لك طبيبك إنك تعاني من عدم تحمل بعض أنواع السكر)الالكتوز مثالً(، أتصل به قبل أخذ هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;لوصفة الطبيب تماماً تناول األقراص وفقا . ً في حال الشك عليك مراجعة الطبيب أو الصيدالني. مقدار الجرعة تبلغ جرعة كوإربيتل العادية قرصاً واحداً في اليوم. يصف عادة طبيبك كوإربيتل عندما لم يؤد عالجك السابق لضغط الدم المرتفع الذي تعاني منه إلى تخفيض ضغط الدم كما يجب. سوف يعلمك طبيبك بكيفية االنتقال من العالج السابق إلى كوإربيتل. طريقة التناول كوإربيتل هو لالستعمال الفموي. إبلع األقراص مع كمية كافية من سائل ما )كوب من الماء مثالً( حاول أخذ جرعتك اليومية في الوقت نفسه كل يوم. من المهم أن تواصل تناول كوإربيتل حتى يأمرك الطيب بإيقافه. يجب بلوغ المفعول األقصى المخفض لضغط الدم بعد بدء العالج ب 6 إلى 8 أسابيع. إذا أخذت كمية كوإربيتل أكثر من التي يجب عليك أخذها. إذا تناولت عرضيا لى الفور. ً عدد كبيرا من القراص اتصل بالطبيب ع ال ينبغي باألطفال أخذ كوإربيتل ال ينبغي إعطاء كوإربيتل لألطفال ما دون ال 18 من العمر. إذا بلع طفل بعض األقراص، اتصل بالطيب على الفور. إذا نسيت أخذ كمية كوإربيتل في حال فوت جرعة يومية عرضيا ض عن ً، خذ الجرعة التالية كالمعتاد ال تتناول جرعة مضاعفة للتعوي الجرعة التي فوتها. إذا كان لديك أي أسئلة إضافية حول استعمال هذه المنتج، إسأل الطبيب أو الصيدالني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل األدوية كلها، قد يسبب كوإربيتل تأثيرات جانبية ال تصيب المرضى كلهم. قد تكون بعض التأثيرات خطيرة فتتطلب عناية طبية. أفيد عن حاالت نادرة من االرتكاسات التحسسية الجلدية )طفح، شرى( وعن تورم موضعي للوجه و/أو الشفتين و/أو اللسان لدى مرضى يأخذون كوإربيتل.</p><p>إذا أصبت بأحد العوارض أعاله أو بضيق نفس، توقف عن أخذ كوإربيتل واتصل بالطبيب على الفور. التأثيرات الجانبية التي أفيد عنها لدى مرضى معالجين بكوإربيتل كانت. تصيب مستعمالً 10 مستعملين من أصل 100 .) التأثيرات الجانبية الشائعة ) إلى &bull; غثيان/ تقيوء. &bull; تبول غير طبيعي. &bull; تعب. &bull; دوار )بما في ذلك عند الوقوف بعد التمدد أو الجلوس(. &bull; قد تظهر فحوصات الدم مستويات مرتفعة من إنزيم يقيس وظيفة العضل والقلب )كرياتينين كيناز( أو مستويات مرتفعة من مواد تقيس الوظيفية الكلوية )نتروجين بولة الدم، كرياتينين(. إذا سبب لك أي من التاثيرات الجانبية هذه مشاكل، تحدث إلى طبيبك. تصيب مستعمالً 10 مستعملين من اصل 1000 .) التاثيرات الجانبية غير الشائعة ) إلى &bull; إسهال. &bull; إنخفاض. ضغط الدم. &bull; إغماء. &bull; زيادة سرعة القلب. &bull; تورد. &bull; تورم. &bull; عسر في الوظيفة الجنسية )مشاكل في األداء الجنسي) &bull; قد تظهر فحوصات الدم مستويات منخفضة من البوتاسيوم والصوديوم في الدم. إذا سبب لك أي من التأثيرات الجانبية هذه مشاكل، تحدث إلى طبيبك. التاثيرات الجانبية التي أفيد عنها منذ تسويق كوإربيتل أفيد عن بعض التأثيرات غير المرغوب بها منذ تسويق كوإربيتل التاثيرات الجانبية غير المعروف معدل حدوثها هي: صداع رنين في األذنين سعال، اضطراب في الذوق، عسر هضم ألم في المفاصل والعضالت، اضطرابات في وظيفة الكبد وقصور في وظيفة الكلى، إرتفاع مستوى البوتاسيوم في الدم وارتكاسات تحسسية مثل الطفح والشرى وتورم الوجه أو الشفتين أو الفم أو الحلق. أفيد كذلك عن حاالت غير شائعة من اليرقان )أصفرار الجلد و/ أو الجزء األبيض من العينين(.</p><p>وبالنسبة إلى أي مزيج لمادتين فاعلتين، ال يمكن استثناء التأثيرات الجانبية الناتجة عن كل مادة منها على حده. التأثيرات الجانبية الناتجة عن اإلربزارتان لوحده أفيد عن ألم في الصدر باإلضافة إلى التأثيرات الجانبية المدرجة أعاله. التأثيرات الجانبية الناتجة عن الهيدروكلوروثيازيد لوحده نقص الشهية، تخريش في المعدة، معص في المعدة، إمساك، يرقان )اصفرار الجلد و/ أو الجزء البيض من العينين)، التهاب البنكرياس الذي يسبب ألما حاداً في الجزء األعلى من المعدة غالباًمع غثيان وتقيؤ، إضطرابات في النوم، إكتئاب، تشوش في الرؤية، نقص في كريات الدم البيض يمكن أن يسبب حاالت عدوى متكررة، حمى، انخفاض في عدد الصفيحات )خلية دموية ضرورية لتخثر الدم(، انخفاض عدد كريات الدم الحمر)فقر دم( يسبب تعبا وشحوبا، ً وصداعاً وضيق نفس عند ممارسة ال رياضة ودواراً مرض كلوى، مشاكل في الرئتين تتضمن ذات الرئة أوتراكم سوائل في الرئتين، زيادة حساسية البشرة تجاه الشمس، إلتهاب األوعية الدموية، مرض جلدي يتميز بانقالع الجلد في كامل انحاء الجسم، ذأب حمامي جلدي يتم التعرف إليه من خالل طفح قد يظهر على الوج ه والعنق وفروة الراس، إرتكاسات تحسسية، تعب وتشنج عضلي، تغيير في النظم القلبي، انخفاض ضغط الدم بعد تغيير وضعية الجسم، تورم الغدد اللعباية، ارتفاع مستويات السكر في الجسم، سكر في البول، ارتفاع بعض أنواع شحوم الدم، ارتفاع مستويات حمض البوليك في الدم مما قد يسبب النقرس.</p><p><strong>أعراض جانبية غير معلومة المعدل )ال يمكن االستدالل عليها من خالل البيانات المتاحة(</strong></p><p>&bull; قصر النظر المفاجئ. &bull; ألم مفاجئ في العين )المياه الزرقاء(. &bull; انصباب المشيمية وقصر النظر الحاد وزرق انسداد الزاوية الثانوي &bull; سرطان الجلد والشفاه )سرطان الجلد غير الميالنيني( من المعروف أن التأثيرات الجانبية الناتجة عن الهيدروكلوروثيازيد قد تزيد مع الجرعات العالية من الهيدروكلوروثيازيد. في حال تفاقم أحد التأثيرات الجانبية أو إذا الحظت تأثيرات جانبية غير مذكورة في هذه النشرة الرجاء أن تعلم الطبيب أو الصيدالني.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ الدواء بعيدا . ً عن متناول األطفال ونظرهم</p><p>ال تستعمل كوإربيتل بعد انقضاء تاريخ الصالحية المدون على علبة الكرتون وعلى الظرف بعد كلمة EXP يشير تاريخ انتهاء الصالحية إلى اليوم األخير من الشهر المذكور. ال تحفظ الدواء في حرارة تفوق 30 درجة مئوية. إحفظ الدواء في علبته األصلية لحمايته من الرطوبة. ال ينبغي رمي األدوية في المياه المبتذلة أو مع النفايات المنزلية. إسأل الصيالني حو كيفية التخلص من األدوية التي لم تعد بحاجة إليها، فمن شأن هذه اإلجراءت حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أقراص كوإربيتل 150 ملجم/5.12 ملجم المغلفة بطبقة رقيقة: &bull; المادتان الفاعلتان هما اإلربزارتان والهيدروكلوروثيازيد. يحتوي كل قرص مغلف بطبقة رقيقة من كوإربيتل 150 ملجم/ 5.12 ملجم على 150 ملجم من اإلربزارتان و 5.12 ملجم من الهيدروكلوروثيازيد. &bull; المكونات األخرى هي الكتوز وحيد التمية، سلولوز دقيق البلورية، كروسكارميلوز الصوديوم، هبروميلوز، ثاني أكسيد السيليكون، ستاريت المغنيزيوم ثاني أكسيد التيتانيوم، ماكرغول 3000، أكسيد الحديديك األحمر وأكسيد الحديديك األصفر والشمع الكوبرنيكي. أقراص كوإربيتل 300 ملجم/5.12 ملجم المغلفة بطبقة رقيقة: &bull; المادتان الفاعلتان هما اإلربزارتان والهيدروكلوروثيازيد. يحتوي كل قرص مغلف بطبقة رقيقة من كوإربيتل 300 ملجم/ 5.12 ملجم على 300 ملجم من اإلربزارتان و 5.12 ملجم من الهيدروكلوروثيازيد. &bull; المكونات األخرى هي الكتوز وحيد التمية، سلولوز دقيق البلورية، كروسكارميلوز الصوديوم، هبروميلوز، ثاني أكسيد السيليكون، ستاريت المغنيزيوم ثاني أكسيد التيتانيوم، ماكرغول 3000، أكسيد الحديديك األحمر وأكسيد الحديديك األصفر والشمع الكوبرنيكي. أقراص كوإربيتل 300 ملجم/25 ملجم المغلفة بطبقة رقيقة: &bull; المادتان الفاعلتان هما اإلربزارتان والهيدروكلوروثيازيد. يحتوي كل قرص مغلف بطبقة رقيقة من كوإربيتل 300 ملجم/25 ملجم على 300 ملجم من اإلربزارتان و 25 ملجم من الهيدروكلوروثيازيد.</p><p>&bull; المكونات األخرى هي الكتوز وحيد التمية، سلولوز دقيق البلورية، كروسكارميلوز الصوديوم، هبروميلوز، ثاني أكسيد السيليكون، ستاريت المغنيزيوم ثاني أكسيد التيتانيوم، ماكرغول 3000، أكسيد الحديديك األحمر وأكسيد الحديديك األصفر والشمع الكوبرنيكي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص كوإربيتل المغفلة بطبقة رقيقة 150 ملجم/ 5.12 ملجم هي أقراص خوخية اللون، ثنائية التحدب بيضاوية الشكل، مع قلب محفور على جهة والرقم 2875 على الجهة األخرى. تأتي أقراص كوإربيتل المغلفة بطبقة رقيقة 150 ملجم/ 5.12 ملجم في ظروف من 14 ، 28 ، 30، بطبقة رقيقة. كما تتوافر علب من ظروف جرعة وحيدة من x156 ًمغلفاًقرصا 98 أو90 ،84 ، 56 قرص مغلف بطبقة رقيقة لالستعمال في المستشفيات. قد ال تكون قياسات العلب كلها مسوقة. أقراص كوإربيتل المغفلة بطبقة رقيقة 300 ملجم/ 5.12 ملجم هي أقراص خوخية اللون، ثنائية التحدب بيضاوية الشكل، مع قلب محفور على جهة والرقم 2876 على الجهة األخرى. تأتي أقراص كوإربيتل المغلفة بطبقة رقيقة 300 ملجم/ 5.12 ملجم في ظروف من 14 ، 28 ، 30، بطبقة رقيقة. كما تتوافر علب من ظروف جرعة وحيدة من x156 ًمغلفاًقرصا 98 أو90 ،84 ، 56 قرص مغلف بطبقة رقيقة لالستعمال في المستشفيات. قد ال تكون قياسات العلب كلها مسوقة. أقراص كوإربيتل المغفلة بطبقة رقيقة 300 ملجم/ 25 ملجم هي أقراص خوخية اللون، ثنائية التحدب بيضاوية الشكل، مع قلب محفور على جهة والرقم 2788 على الجهة األخرى. تأتي أقراص كوإربيتل المغلفة بطبقة رقيقة 300 ملجم/ 25 ملجم في ظروف من 14 ، 28 ، 30، بطبقة رقيقة. كما تتوافر علب من ظروف جرعة وحيدة من x156 ًمغلفاًقرصا 98 أو90 ،84 ، 56 قرص مغلف بطبقة رقيقة لالستعمال في المستشفيات. قد ال تكون قياسات العلب كلها مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>SANOFI لصالح: الدوائية مصنع األدوية بالقصيم الشركة السعودية للصناعات الدوائية والمستلزمات الطبية. المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             ابريل 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CoIrbetel 300 mg/12.5 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Excipient:
Each film-coated tablet contains 89.5 mg of lactose (as lactose monohydrate). For a full list of
excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Biconvex, oval-shaped film-coated tablets, engraved with a heart on one side and the number «
2876 » on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CoIrbetel can be taken once daily, with or without food. Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended. When clinically appropriate direct change from monotherapy to the fixed combinations may be considered:</p><p>&fnof; CoIrbetel 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;</p><p>&fnof; CoIrbetel 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoIrbetel 150 mg/12.5 mg.</p><p>&fnof; CoIrbetel 300 mg/25 mg may be administered in patients insufficiently controlled by CoIrbetel 300 mg/12.5 mg.</p><p>Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. When necessary, CoIrbetel may be administered with another antihypertensive medicinal product (see section 4.5).</p><p><u>Renal impairment:</u></p><p>due to the hydrochlorothiazide component, CoIrbetel is not recommended for patients with severe renal dysfunction (creatinine clearance &lt; 30 ml/min). Loop diuretics are preferred to thiazides in this population. No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is &ge; 30 ml/min (see sections 4.3 and 4.4).</p><p><u>Hepatic impairment:</u></p><p>CoIrbetel is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function. No dosage adjustment of CoIrbetel is necessary in patients with mild to moderate hepatic impairment (see section 4.3). Elderly patients: no dosage adjustment of CoIrbetel is necessary in elderly patients.</p><p><u>Paediatric patients:</u></p><p>CoIrbetel is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ƒ Hypersensitivity to the active substances, to any of the excipients (see section 6.1), or
to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamidederived substance)
ƒ Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
ƒ Severe renal impairment (creatinine clearance < 30 ml/min)
ƒ Refractory hypokalaemia, hypercalcaemia
ƒ Severe hepatic impairment, biliary cirrhosis and cholestasis
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypotension - Volume-depleted patients:</u></p><p>CoIrbetel has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension. Symptomatic hypotension may be expected to occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before initiating therapy with CoIrbetel.</p><p>&nbsp;</p><p><u>Renal artery stenosis - Renovascular hypertension:</u></p><p>there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists. While this is not documented with CoIrbetel, a similar effect should be anticipated.</p><p><u>Renal impairment and kidney transplantation: </u>when CoIrbetel is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended. There is no experience regarding the administration of CoIrbetel in patients with a recent kidney transplantation. CoIrbetel should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.3). Thiazide diuretic-associated azotemia may occur in patients with impaired renal function. No dosage adjustment is necessary in patients with renal impairment whose creatinine clearance is &ge; 30 ml/min. However, in patients with mild to moderate renal impairment (creatinine clearance &ge; 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered with caution.</p><p><u>Hepatic impairment:</u></p><p>thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. There is no clinical experience with CoIrbetel in patients with hepatic impairment.</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</u>: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. P</p><p><u>rimary aldosteronism: </u>patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of CoIrbetel is not recommended.</p><p><u>Metabolic and endocrine effects: </u>thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during thiazide therapy. Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however, at the 12.5 mg dose contained in CoIrbetel, minimal or no effects were reported. Hyperuricaemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.</p><p><u>Electrolyte imbalance: </u>as for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals. Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalaemia, hyponatraemia, and hypochloremic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting. Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with irbesartan may reduce diuretic-induced hypokalaemia. The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH. Conversely, due to the irbesartan component of CoIrbetel hyperkalaemia might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with CoIrbetel (see section 4.5). There is no evidence that irbesartan would reduce or prevent diuretic-induced hyponatraemia. Chloride deficit is generally mild and usually does not require treatment. Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.&nbsp;</p><p>Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function. Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnaesemia.</p><p><u>Lithium: </u>the combination of lithium and CoIrbetel is not recommended (see section 4.5).</p><p><u>Anti-doping test: </u>hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.</p><p><u>General: </u>in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotemia, oliguria, or rarely acute renal failure. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischemic cardiopathy or ischemic cardiovascular disease could result in a myocardial infarction or stroke. Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history. Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics. Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re- administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><u>Pregnancy</u>: Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Lactose:</u> this medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p><u>Choroidal effusion</u>, acute myopia and secondary angle-closure glaucoma:&nbsp;</p><p>Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as&nbsp;possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p><strong><u>Non-melanoma skin cancer</u></strong></p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC. Patients taking HCTZ should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Other antihypertensive agents:</u></p><p>the antihypertensive effect of CoIrbetel may be increased with the concomitant use of other antihypertensive agents. Irbesartan and hydrochlorothiazide (at doses up to 300 mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other antihypertensive agents including calcium channel blockers and beta-adrenergic blockers. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with irbesartan with or without thiazide diuretics unless the volume depletion is corrected first (see section 4.4).</p><p><u>Lithium</u>: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with CoIrbetel. Therefore, the combination of lithium and CoIrbetel is not recommended (see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><u>Medicinal products affecting potassium:</u> the potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see section 4.4).</p><p><u>Medicinal products affected by serum potassium disturbances: </u>periodic monitoring of serum potassium is recommended when CoIrbetel is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).</p><p><u>Non-steroidal anti-inflammatory drugs:</u> when angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</p><p>As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><u>Additional information on irbesartan interactions</u>: in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by co-administration of irbesartan.</p><p><u>Additional information on hydrochlorothiazide interactions: </u>when administered concurrently, the following medicinal products may interact with thiazide diuretics: Alcohol: potentiation of orthostatic hypotension may occur; Antidiabetic medicinal products (oral agents and insulins): dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4); Colestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. CoIrbetel should be taken at least one hour before or four hours after these medications; Corticosteroids, ACTH: electrolyte depletion, particularly hypokalaemia, may be increased; Digitalis glycosides: thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias (see section 4.4); Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal antiinflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients; Pressor amines (e.g. noradrenaline): the effect of pressor amines may be decreased, but not sufficiently to preclude their use;</p><p>&nbsp;Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide; Antigout medicinal products: dosage adjustments of antigout medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence of hypersensitivity reactions to allopurinol; Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly; Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides. Anticholinergic agents (e.g. atropine, beperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects. Carbamazepine: concomitant use of carbamazepine and hydrochlorothiazide has been associated with the risk of symptomatic hyponatraemia. Electrolytes should be monitored during concomitant use. If possible, another class of diuretics should be used;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy:</p><table border="1" cellspacing="1" cellpadding="1" style="width:797px"><tbody><tr><td style="width:794px"><p>The use of AIIRAs is not recommended during the first trimester of pregnancy (see section4.4). The use of AIIRAs is contraindicated during the second and third&nbsp;trimesters of pregnancy(see sections 4.3 and 4.4).</p></td></tr></tbody></table><p>Pregnancy category D Thiazides cross the placental barrier and appear in cord blood. They may cause a decrease in placental perfusion, foetal electrolyte disturbances and possibly other reactions that have occurred in the adults. Cases of neonatal thrombocytopenia, or foetal or neonatal jaundice have been reported with maternal thiazide therapy. Since CoIrbetel contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy. with the following: There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second&nbsp;and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia. Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease. Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used. Since CoIrbetel contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy. Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started. Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4). Thiazides cross the placental barrier and appear in cord blood. They may cause a decrease in placental perfusion, foetal electrolyte disturbances and possibly other reactions that have occurred in the adults. Cases of neonatal thrombocytopenia, or foetal or neonatal jaundice have been reported with maternal thiazide therapy. Since CoIrbetel contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.</p><p>Lactation:</p><p>Because no information is available regarding the use of CoIrbetel during breast-feeding, CoIrbetel is not recommended and alternative treatments with better established safety profiles during breast- feeding are preferable, especially while nursing a newborn or preterm infant. Hydrochlorothiazide: Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production. The use of CoIrbetel during breast feeding is not recommended. If CoIrbetel is used during breast feeding, doses should be kept&nbsp;as low as possible.</p><p>Fertility:</p><p>Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Based on its pharmacodynamic properties, CoIrbetel is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Irbesartan/hydrochlorothiazide combination:</u></p><p>Among 898 hypertensive patients who received various doses of irbesartan/hydrochlorothiazide (range: 37.5 mg/6.25 mg to 300 mg/25 mg) in placebo-controlled trials, 29.5% of the patients experienced adverse reactions. The most commonly reported ADRs were dizziness (5.6%), fatigue (4.9%), nausea/vomiting (1.8%), and abnormal urination (1.4%). In addition increases in blood urea nitrogen (BUN) (2.3%), creatine kinase (1.7%) and creatinine (1.1%) were also commonly observed in the trials.</p><p>Table 1 gives the adverse reactions observed from spontaneous reporting and in placebocontrolled trials.</p><p>The frequency of adverse reactions listed below is defined using the following convention:</p><p>very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Table 1:</strong> Adverse Reactions in Placebo-Controlled Trials and Spontaneous Reports*</p><p><em>&nbsp;Investigations: </em></p><p>Common: &nbsp;increases in blood urea nitrogen (BUN), creatinine and creatine kinase</p><p>Uncommon: decreases in serum potassium and sodium</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders: </em></p><p>Uncommon: syncope, hypotension, tachycardia, oedema</p><p>&nbsp;</p><p><em>Nervous system disorders: </em></p><p>Common: dizziness</p><p>Uncommon: orthostatic dizziness</p><p>Not known: headache</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear and labyrinth disorders:</em></p><p>&nbsp;Not known: tinnitus</p><p><em>&nbsp;Respiratory, thoracic and mediastinal disorders:</em></p><p>&nbsp;Not known: cough</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders: Renal and urinary disorders: Musculoskeletal and connective</em></p><p>Common: nausea/vomiting</p><p>Uncommon: diarrhoea</p><p>Not known: dyspepsia, dysgeusia</p><p>Common: abnormal urination Not known: impaired renal function including isolated cases of renal failure in patients at risk (see section 4.4)</p><p>Uncommon: swelling extremity</p></td></tr><tr><td style="vertical-align:top"><p><em>tissue disorders:</em></p><p>&nbsp;Not known: arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders: </em></p><p>Not known: hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders: </em></p><p>Uncommon: flushing</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions: </em></p><p>Common: fatigue</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders:</em></p><p>&nbsp;Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders:</p><p>Not known: hepatitis, abnormal liver function</p><p><em>&nbsp;Hepatobiliary disorders </em></p><p>Uncommon jaundice</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders: </em></p><p>Uncommon: sexual dysfunction, libido changes</p></td></tr></tbody></table><p>&nbsp;</p><p>* Frequency for adverse reactions detected by spontaneous reports is described as &ldquo;not known&rdquo;</p><p><u>Additional information on individual components:</u> in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with CoIrbetel. Tables 2 and 3 below detail the adverse reactions reported with the individual components of CoIrbetel.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Table 2</strong>: Adverse reactions reported with the use of irbesartan alone General disorders and</p><p>&nbsp;Uncommon: chest pain</p><p><u>administration site conditions:</u></p><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Table 3</strong>: Adverse reactions (regardless of relationship to medicinal product) reported with the use of</p></td></tr><tr><td style="vertical-align:top"><p>hydrochlorothiazide alone</p><p>&nbsp;Investigations:</p><p>Not known: electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders:</p><p>Not known: cardiac arrhythmias</p><p>Blood and lymphatic system disorders:</p><p>&nbsp;Not known: aplastic anaemia, bone marrow depression, neutropenia/ agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders:</p><p>Not known: vertigo, paraesthesia, light-headedness, restlessness</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders:</p><p>Not known: transient blurred vision, xanthopsia, Choroidal effusion</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders:</p><p>Not known: respiratory distress (including pneumonitis and pulmonary oedema)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders:</p><p>Not known: pancreatitis, anorexia, diarrhoea, constipation, gastric irritation, sialadenitis, loss of appetite</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders:</p><p>&nbsp;Not known: interstitial nephritis, renal dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders:</p><p>&nbsp;Not known: anaphylactic reactions, toxic epidermal necrolysis, necrotizing angiitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective</p><p>&nbsp;Not known: weakness, muscle spasm</p></td></tr><tr><td style="vertical-align:top"><p>tissue disorders:</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders:</p><p>&nbsp;Not known: postural hypotension</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions:</p><p>&nbsp;Not known: fever</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders:</p><p>Not known: jaundice (intrahepatic cholestatic jaundice)</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders:</p><p>Not known: depression, sleep disturbances</p></td></tr></tbody></table><p>The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide. Description of selected adverse reactions &bull; Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics. If cases are to be reported for these substances in the future, the appropriate procedure should be used to update the product information accordingly. &bull; Non-melanoma skin cancer Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).</p><p>&nbsp;</p><p>To report any side effect(s):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662 SFDA</p><p>&nbsp;Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with CoIrbetel. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends on the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly. The most likely manifestations of irbesartan overdose are expected to be hypotension and tachycardia; bradycardia might also occur.&nbsp;</p><p>Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloremia, hyponatraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products. Irbesartan is not removed by haemodialysis. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: angiotensin-II antagonists, combinations ATC code: C09DA04. CoIrbetel is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensinII levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses in patients without risk of electrolyte imbalance (see sections 4.4 and 4.5). Irbesartan does not inhibit ACE (kininaseII), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity. Hydrochlorothiazide is a thiazide diuretic. The mechanism of antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics. With hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while the action persists for approximately 6-12 hours. The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges. The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg. The combination of 300 mg irbesartan and 12.5 mg hydrochlorothiazide resulted in an overall placebo-subtracted systolic/diastolic reductions of up to 13.6/11.5 mm Hg.Limited clinical data (7 out of 22 patients) suggest that patients not controlled with the 300 mg/12.5 mg combination may respond when uptitrated to 300 mg/25 mg. In these patients, an incremental blood pressure lowering effect was observed for both systolic blood pressure (SBP) and diastolic blood pressure (DBP) (13.3 and 8.3 mm Hg, respectively). Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours postdosing) of 12.9/6.9 mm Hg in patients with mild-to-moderate hypertension. Peak effects occurred at 3-6 hours. When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebosubtracted systolic/diastolic reductions of 15.8/10.0 mm Hg. When measured by ambulatory blood pressure monitoring, the trough to peak effects of CoIrbetel 150 mg/12.5 mg were 100%. The trough to peak effects measured by cuff during office visits were 68% and 76% for CoIrbetel 150 mg/12.5 mg and CoIrbetel 300 mg/12.5 mg, respectively. These 24-hour effects were observed without excessive blood pressure lowering at peak and are consistent with safe and effective blood-pressure lowering over the once-daily dosing interval. In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of irbesartan gave an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mm Hg. The blood pressure lowering effect of irbesartan in combination with hydrochlorothiazide is apparent after the first dose and substantially present within 1-2 weeks, with the maximal effect occurring by 6-8 weeks. In long-term follow-up studies, the effect of irbesartan/hydrochlorothiazide was maintained for over one year. Although not specifically studied with the CoIrbetel, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide. The effect of the combination of irbesartan and hydrochlorothiazide on morbidity and mortality has not been studied. Epidemiological studies have shown that long term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity. There is no difference in response to CoIrbetel, regardless of age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of non-black patients. Efficacy and safety of CoIrbetel as initial therapy for severe hypertension (defined as SeDBP &ge; 110 mmHg) was evaluated in a multicenter, randomized, double-blind, active-controlled, 8-week, parallel-arm study. A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically force- titrated (before assessing the response to the lower dose) after one week to irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively. The study recruited 58% males. The mean age of patients was 52.5 years, 13% were &ge; 65 years of age, and just 2% were &ge; 75 years of age. Twelve percent (12%) of patients were diabetic, 34% were hyperlipidemic and the most frequent cardiovascular condition was stable&nbsp;angina pectoris in 3.5% of the participants. The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP &lt; 90 mmHg) at Week 5 of treatment. Forty-seven percent (47.2%) of patients on the combination achieved trough SeDBP &lt; 90 mmHg compared to 33.2% of patients on irbesartan (p = 0.0005). The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p &lt; 0.0001). The types and incidences of adverse events reported for patients treated with the combination were similar to the adverse event profile for patients on monotherapy. During the 8-week treatment period, there were no reported cases of syncope in either treatment group. There were 0.6% and 0% of patients with hypotension and 2.8% and 3.1% of patients with dizziness as adverse reactions reported in the combination and monotherapy groups, respectively. Non-melanoma skin cancer Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed. One study included a population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and 172,462 population controls, respectively. High HCTZ use (&ge;50,000 mg cumulative) was associated with an adjusted OR of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68- 4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to HCTZ: 633 cases of lip-cancer were matched with 63,067 population controls, using a risk-set sampling strategy. A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of hydrochlorothiazide and irbesartan has no effect on the pharmacokinetics of either medicinal product. Irbesartan and hydrochlorothiazide are orally active agents and do not require biotransformation for their activity. Following oral administration of CoIrbetel, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively. Food does not affect the bioavailability of CoIrbetel. Peak plasma concentration occurs at 1.5-2 hours after oral administration for irbesartan and 1-2.5 hours for hydrochlorothiazide. Plasma protein binding of irbesartan is approximately 96%, with negligible binding to cellular blood components. The volume of distribution for irbesartan is 53-93 litres. Hydrochlorothiazide is 68% protein-bound in the plasma, and its apparent volume of distribution is 0.83-1.14 l/kg. Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg was&nbsp;observed; the mechanism for this is unknown. The total body and renal clearance are 157- 176 and 3.0-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11- 15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (&ge; 65 years) than those of young subjects (18-40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in elderly patients. The mean plasma half-life of hydrochlorothiazide reportedly ranges from 5-15 hours. Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or intravenous administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidneys. At least 61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier, and is excreted in breast milk.</p><p>Renal impairment:</p><p>in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. In patients with creatinine clearance &lt; 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.</p><p>Hepatic impairment:</p><p>in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered. Studies have not been performed in patients with severe hepatic impairmen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months. There were no toxicological findings observed of relevance to human therapeutic use. The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):</p><p>&fnof; kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;</p><p>&fnof; slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit);</p><p>&fnof; stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few&nbsp;rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day. These lesions were not observed in macaques;</p><p>&fnof; decreases in serum potassium due to hydrochlorothiazide and partly prevented when hydrochlorothiazide was given in combination with irbesartan.&nbsp;</p><p>Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan (blockade of angiotensin-II-induced inhibition of renin release, with stimulation of the renin-producing cells) and occur also with angiotensin converting enzyme inhibitors. These findings appear to have no relevance to the use of therapeutic doses of irbesartan/hydrochlorothiazide in humans. No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at doses that produced maternal toxicity. The effects of the irbesartan/hydrochlorothiazide combination on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone. However, another angiotensin-II antagonist affected fertility parameters in animal studies when given alone. These findings were also observed with lower doses of this other angiotensin-II antagonist when given in combination with hydrochlorothiazide. There was no evidence of mutagenicity or clastogenicity with the irbesartan/hydrochlorothiazide combination. The carcinogenic potential of irbesartan and hydrochlorothiazide in combination has not been evaluated in animal studies. Irbesartan: there was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (&ge; 250 mg/kg/day in rats and &ge; 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high doses (&ge; 500 mg/kg/day) degenerative changes in the kidneys (such as interstitial nephritis, tubular distention, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in macaques at &ge; 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. There was no evidence of mutagenicity, clastogenicity or carcinogenicity. Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit. Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: Lactose monohydrate Microcrystalline cellulose Croscarmellose sodium Hypromellose Silicon dioxide Magnesium stearate Film-coating: Lactose monohydrate Hypromellose Titanium dioxide Macrogol 3000 Red and yellow ferric oxides Carnauba wax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartons of 14 film-coated tablets; 1 blister card of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. Cartons of 28 film-coated tablets; 2 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. Cartons of 30 film-coated tablets; 2 blister cards of 15 film-coated tablets in PVC/PVDC/Aluminium blisters. Cartons of 56 film-coated tablets; 4 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. Cartons of 84 film-coated tablets; 6 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. Cartons of 90 film-coated tablets; 6 blister cards of 15 film-coated tablets in PVC/PVDC/Aluminium blisters. Cartons of 98 film-coated tablets; 7 blister cards of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. Cartons of 56 x 1 film-coated tablets; 7 blister cards of 8 x 1 film-coated tablets each in&nbsp;PVC/PVDC/Aluminium perforated unit dose blisters. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: SANOFI
For: SPIMACO AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries & Medical Appliance Corporation
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>